ArticleJournal of gastroenterology and hepatology2026

Comment on Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial.

Hrithika Jeswani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.